Teva halts output at U.S. drug plant after FDA flags concerns | Reuters
Parenteral Drugs: Tracking New Drug Approvals - DCAT Value Chain Insights
METOCLOPRAMIDE HCL 5MG/ML - RX Products
U.S. Court of Appeals Rules In Lilly's Favor On Alimta Vitamin Regimen Patent
PPT – Global Thyroid Cancer Drugs Market Overview And Top Key Players by 2030 PowerPoint presentation | free to download - id: 922367-YjYwO
Teva Parenteral Medicines Initiates Voluntary Nationwide Recall of Select Lots of Adrucil® (fluorouracil injection, USP) 5 g/100 mL (50 mg/mL) Due to Particulate Matter | Business Wire
DAUNORUBICIN Hydrochloride Injection
Teva Parenteral Medicines, Inc. Irvine, CA. Form 483 (Inspectional Observations). 7/13/09 – 7/24/09
Earnings Preview: What To Expect From Teva Pharmaceutical On Monday
Patent Docs: Eli Lilly & Co. v. Teva Parenteral Medicines, Inc. (Fed. Cir. 2012)
Teva Parenteral Medicines Initiates Voluntary Nationwide Recall of Select Lots of Adrucil® (fluorouracil injection, USP) 5 g/100 mL (50 mg/mL) Due to Particulate Matter | Business Wire
Metoclopramide: it actually works!? « metajournal.com
Eli Lilly & Co. v. Teva Parenteral Medicines, Inc. (Fed. Cir. 2012) | McDonnell Boehnen Hulbert & Berghoff LLP - JDSupra
Teva's 70+ manufacturing sites could be halved in efficiency drive